Figure 6
Anti-tumor efficacy and Cross Action of Ub-enriched proteins Vaccine in EL4 and B16-F10 tumor models. C57BL/6 mice were injected s.c. with 1 × 106 EL4 tumor cells (A-C) and 1 × 106 B16-F10 tumor cells (D-F). Seven days later, mice established tumors were divided randomly into groups of 5 animals each with comparable mean tumor sizes. Two groups were then left untreated; other four were primed with single i.n. and twice s.c. vaccination n days 7, 9 and 11 with Vx3(A7) protein, Ub-depleted proteins and Ub-enriched proteins isolated from EL4 and B16 tumor cells respectively and separately. The tumor growth was measured three times a week (A, B, D, E). (A, D) Representing the tumor size of individual mice for each group. (C, F) The percent survival time of EL4 and B16 tumor models groups respectively. This data is from two experiments with similar results.